BioMimetic Therapeutics, a biotechnology company specializing in the development and commercialization of orthopedic, spine and sports injury products, has reported a fourth quarter 2010 revenue of $400,000, the same amount reported in the fourth quarter of 2009, according to a company news release.
BioMimetic also reported year-end revenue of $1.5 million, down from last year's $1.6 million revenue. According to BioMimetic President and CEO Samuel Lynch, much of 2010 was devoted to pushing the company's lead product candidate, Augment Bone Graft, through the Food and Drug Administration's approval process. Other lead products underwent clinical trials and development as well, according to the company news release.
Read the company news release about BioMimetic Therapeutics' 4Q financial results.
Read other coverage about BioMimetic Therapeutics:
- FDA to Review Premarket Approval Application for BioMimetic Therapeutics' Augment Bone Graft
- Millennium Research Group: Bone Graft Substitute Market to Reach $2.3B by 2015
BioMimetic also reported year-end revenue of $1.5 million, down from last year's $1.6 million revenue. According to BioMimetic President and CEO Samuel Lynch, much of 2010 was devoted to pushing the company's lead product candidate, Augment Bone Graft, through the Food and Drug Administration's approval process. Other lead products underwent clinical trials and development as well, according to the company news release.
Read the company news release about BioMimetic Therapeutics' 4Q financial results.
Read other coverage about BioMimetic Therapeutics:
- FDA to Review Premarket Approval Application for BioMimetic Therapeutics' Augment Bone Graft
- Millennium Research Group: Bone Graft Substitute Market to Reach $2.3B by 2015